Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ABL1 | P00519 | 2/20 | 0.46 |
| ▸ | SMYD3 | Q9H7B4 | 6/20 | 0.44 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24956359 | 0.94 | NPC1 (0.52) | NPC1RAB9ATSHRSMN1; SMN2ABL1 | |
| SCHEMBL24956358 | 0.94 | NPC1 (0.56) | NPC1RAB9ATSHRSMN1; SMN2ABL1 | |
| SCHEMBL24960109 | 0.88 | TGFBR1 (0.46) | NPC1RAB9ATSHRSMN1; SMN2ABL1 | |
| SCHEMBL24958860 | 0.85 | ABL1 (0.45) | NPC1RAB9ATSHRSMN1; SMN2ABL1 | |
| SCHEMBL24958738 | 0.80 | NPC1 (0.41) | NPC1RAB9ATSHRSMN1; SMN2HPGD | |
| SCHEMBL24956354 | 0.80 | SMYD3 (0.51) | NPC1RAB9ASMN1; SMN2ABL1SMYD3 | |
| SCHEMBL24958916 | 0.77 | ABL1 (0.53) | NPC1RAB9ATSHRSMN1; SMN2ABL1 | |
| SCHEMBL105413 | 0.75 | TAS1R3 (0.53) | NPC1RAB9ACNR2HPGDCYP2C9 | |
| SCHEMBL24960108 | 0.75 | ABL1 (0.48) | NPC1RAB9ATSHRSMN1; SMN2ABL1 | |
| SCHEMBL25093457 | 0.74 | NPC1 (0.45) | NPC1RAB9ATSHRSMN1; SMN2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230021705-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230021705-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | NPC1 1188/4885RAB9A 478/4885TSHR 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.